Titre : Protéines d'activation de la GTPase

Protéines d'activation de la GTPase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neoplasm Recurrence, Local

Questions fréquentes et termes MeSH associés

Général 1

#1

Erreur lors de la génération.

Veuillez réessayer ultérieurement.
GTPase-Activating Proteins
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines d'activation de la GTPase : Questions médicales les plus fréquentes", "headline": "Protéines d'activation de la GTPase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines d'activation de la GTPase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-25", "dateModified": "2025-04-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines d'activation de la GTPase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Régulateurs des protéines G", "url": "https://questionsmedicales.fr/mesh/D020555", "about": { "@type": "MedicalCondition", "name": "Régulateurs des protéines G", "code": { "@type": "MedicalCode", "code": "D020555", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.325" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéines d'activation de la ras GTPase", "alternateName": "ras GTPase-Activating Proteins", "url": "https://questionsmedicales.fr/mesh/D020703", "about": { "@type": "MedicalCondition", "name": "Protéines d'activation de la ras GTPase", "code": { "@type": "MedicalCode", "code": "D020703", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.325.150.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine p120 d'activation de la ras GTPase", "alternateName": "p120 GTPase Activating Protein", "url": "https://questionsmedicales.fr/mesh/D020729", "about": { "@type": "MedicalCondition", "name": "Protéine p120 d'activation de la ras GTPase", "code": { "@type": "MedicalCode", "code": "D020729", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.325.150.500.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Protéines RGS", "alternateName": "RGS Proteins", "url": "https://questionsmedicales.fr/mesh/D020710", "about": { "@type": "MedicalCondition", "name": "Protéines RGS", "code": { "@type": "MedicalCode", "code": "D020710", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.325.150.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Protéines d'activation de la GTPase", "alternateName": "GTPase-Activating Proteins", "code": { "@type": "MedicalCode", "code": "D020690", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "René Rasche", "url": "https://questionsmedicales.fr/author/Ren%C3%A9%20Rasche", "affiliation": { "@type": "Organization", "name": "Institute of Biochemistry, University Münster, Germany." } }, { "@type": "Person", "name": "Daniel Kümmel", "url": "https://questionsmedicales.fr/author/Daniel%20K%C3%BCmmel", "affiliation": { "@type": "Organization", "name": "Institute of Biochemistry, University Münster, Germany." } }, { "@type": "Person", "name": "Manil Kanade", "url": "https://questionsmedicales.fr/author/Manil%20Kanade", "affiliation": { "@type": "Organization", "name": "Indian Institute of Science Education and Research, Pune, India." } }, { "@type": "Person", "name": "Pananghat Gayathri", "url": "https://questionsmedicales.fr/author/Pananghat%20Gayathri", "affiliation": { "@type": "Organization", "name": "Indian Institute of Science Education and Research, Pune, India." } }, { "@type": "Person", "name": "Qingqing Dai", "url": "https://questionsmedicales.fr/author/Qingqing%20Dai", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Jena, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.", "datePublished": "2022-11-13", "url": "https://questionsmedicales.fr/article/36371582", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-022-12760-1" } }, { "@type": "ScholarlyArticle", "name": "Feasibility of local therapy for recurrent pancreatic cancer.", "datePublished": "2022-05-24", "url": "https://questionsmedicales.fr/article/35641368", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.pan.2022.05.004" } }, { "@type": "ScholarlyArticle", "name": "Ultrasound Assessment of Skin Tumors Local Recurrence.", "datePublished": "2023-05-17", "url": "https://questionsmedicales.fr/article/37195073", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jum.16255" } }, { "@type": "ScholarlyArticle", "name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.", "datePublished": "2023-06-26", "url": "https://questionsmedicales.fr/article/37442715", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejso.2023.06.023" } }, { "@type": "ScholarlyArticle", "name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.", "datePublished": "2022-11-21", "url": "https://questionsmedicales.fr/article/36371607", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/his.14839" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Régulateurs des protéines G", "item": "https://questionsmedicales.fr/mesh/D020555" }, { "@type": "ListItem", "position": 6, "name": "Protéines d'activation de la GTPase", "item": "https://questionsmedicales.fr/mesh/D020690" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines d'activation de la GTPase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines d'activation de la GTPase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-29", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Général", "headline": "Général sur Protéines d'activation de la GTPase", "description": "Erreur lors de la génération.", "url": "https://questionsmedicales.fr/mesh/D020690?mesh_terms=Neoplasm+Recurrence,+Local#section-général" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Erreur lors de la génération.", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Veuillez réessayer ultérieurement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 21/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

René Rasche

2 publications dans cette catégorie

Affiliations :
  • Institute of Biochemistry, University Münster, Germany.

Daniel Kümmel

2 publications dans cette catégorie

Affiliations :
  • Institute of Biochemistry, University Münster, Germany.

Manil Kanade

2 publications dans cette catégorie

Affiliations :
  • Indian Institute of Science Education and Research, Pune, India.

Pananghat Gayathri

2 publications dans cette catégorie

Affiliations :
  • Indian Institute of Science Education and Research, Pune, India.

Qingqing Dai

2 publications dans cette catégorie

Affiliations :
  • Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Jena, Germany.
  • Else Kröner Graduate School for Medical Students "Jena School for Ageing Medicine (JSAM)", Jena University Hospital, Jena, Germany.

Fei Song

2 publications dans cette catégorie

Affiliations :
  • Department of Urology, Jena University Hospital, Jena, Germany.

Jun Matsuda

2 publications dans cette catégorie

Affiliations :
  • Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada; Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.
Publications dans "Protéines d'activation de la GTPase" :

Tomoko Takano

2 publications dans cette catégorie

Affiliations :
  • Division of Nephrology, McGill University Health Centre, Montreal, Quebec, Canada; Research Institute, McGill University Health Centre, Montreal, Quebec, Canada. Electronic address: tomoko.takano@mcgill.ca.
Publications dans "Protéines d'activation de la GTPase" :

Qiaojia Zheng

2 publications dans cette catégorie

Affiliations :
  • Marine and Agricultural Biotechnology Laboratory, Institute of Oceanography, Minjiang University, Fuzhou, China.

Zhi Yu

2 publications dans cette catégorie

Affiliations :
  • Marine and Agricultural Biotechnology Laboratory, Institute of Oceanography, Minjiang University, Fuzhou, China.
  • College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China.

Yanping Yuan

2 publications dans cette catégorie

Affiliations :
  • College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China.

Danli Sun

2 publications dans cette catégorie

Affiliations :
  • Marine and Agricultural Biotechnology Laboratory, Institute of Oceanography, Minjiang University, Fuzhou, China.

Yakubu Saddeeq Abubakar

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Nigeria.

Jie Zhou

2 publications dans cette catégorie

Affiliations :
  • College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China.

Zonghua Wang

2 publications dans cette catégorie

Affiliations :
  • Marine and Agricultural Biotechnology Laboratory, Institute of Oceanography, Minjiang University, Fuzhou, China.
  • College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China.

Huawei Zheng

2 publications dans cette catégorie

Affiliations :
  • Marine and Agricultural Biotechnology Laboratory, Institute of Oceanography, Minjiang University, Fuzhou, China.

Lorna O'Donoghue

1 publication dans cette catégorie

Affiliations :
  • UCD School of Medicine, University College Dublin, UCD Conway Institute, Belfield, Dublin 4, Ireland.
  • Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, 123 St. Stephen's Green 123, Dublin 2, Ireland.
Publications dans "Protéines d'activation de la GTPase" :

Albert Smolenski

1 publication dans cette catégorie

Affiliations :
  • UCD School of Medicine, University College Dublin, UCD Conway Institute, Belfield, Dublin 4, Ireland.
  • Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, 123 St. Stephen's Green 123, Dublin 2, Ireland.
Publications dans "Protéines d'activation de la GTPase" :

Yu Huang

1 publication dans cette catégorie

Affiliations :
  • Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-Environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.

Shuangquan Yan

1 publication dans cette catégorie

Affiliations :
  • Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-Environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.

Sources (10000 au total)

Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.

Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR.... This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g... For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien... This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...

Feasibility of local therapy for recurrent pancreatic cancer.

Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap... We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c... A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ... Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....

Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.

Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders... A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana... 388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ... A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...

Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.

The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that... We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w... This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ... The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer... CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ... Level III, therapeutic study....

Risk Factors of Second Local Recurrence in Surgically Treated Recurrent Brain Metastases: An Exploratory Analysis.

A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca... Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro... Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs... A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...

Applying a neoscore in locally advanced rectal cancer is beneficial in predicting local recurrences after surgery.

The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic... One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ... HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'... We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....

Surgery of resectable local recurrence following colorectal cancer: Compartmental surgery improves local control.

This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC).... An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center.... In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,... Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....

Recurrent RET fusions in fibrosarcoma-like neoplasms in adult viscera: expanding the clinicopathological and genetic spectrum.

RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ... Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc... Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....